金斯瑞生物科技(01548.HK):傳奇生物完成後續公開發售
格隆匯12月21日丨金斯瑞生物科技(01548.HK)發佈公吿,傳奇生物(公司非全資附屬公司,其股份以美國存托股份形式於美國納斯達克全球精選市場上市)已通知公司,後續公開發售(包括金斯瑞參與)已於2021年12月20日(紐約時間)完成。傳奇生物於後續公開發售中以公開發售價每股美國存托股份40.00美元發行861.56萬股美國存托股份,每股代表兩股普通股。完成時發行的美國存托股份數目包括承銷商行使購股權購買111.56萬股額外美國存托股份。
緊隨後續公開發售(包括金斯瑞參與)完成後,公司於傳奇生物的股權已被攤薄,由當前的約58.41%下降至按全面攤薄基準計的56.61%(未計根據僱員購股權計劃將予發行的股份)。後續公開發售完成後,傳奇生物將繼續為公司的直接非全資附屬公司,傳奇生物的財務業績將繼續合併入公司的財務報表。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.